Business
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference
CHICAGO--(BUSINESS WIRE)-- Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid
About this update from Exicure, Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nExicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference, occurring October 3-4, 2022.\n\nThe presentation will be available for on-demand viewing using the virtual conference link beginning October 3, 2022 at 4:00 PM EST and will be archived for 120 days: https://wsw.com/webcast/chard14/xcur/1943406\n\nExicure will be taking 1x1 investor meetings with registered conference attendees.\n\nAbout Exicure\n\nExicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening. For further information, see www.exicuretx.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220901005015/en/\n\nMedia:\nKaren Sharma\nMacDougall\n781-235-3060\[email protected]\n\nSource: Exicure, Inc.","length":3240,"tagName":"div"}]